{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:35:27Z","timestamp":1791279327116,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003831","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"record-id":"30937"},{"DOI":"10.1002\/14651858.cd003831","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000}}],"reference-count":36,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003831.pub2","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T15:40:42Z","timestamp":1497022842000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Celecoxib for rheumatoid arthritis"],"prefix":"10.1002","volume":"2017","author":[{"given":"Sarah E","family":"Garner","sequence":"first","affiliation":[{"name":"National Institute for Health and Care Excellence (NICE); Science Policy and Research; MidCity Place 71 High Holborn London UK WC1V 6NA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dogan","family":"Fidan","sequence":"additional","affiliation":[{"name":"Aventis Pharma Ltd.; Health Economics Unit; Flat 8 291 Boardwalk Place London UK E14 56E"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth R","family":"Frankish","sequence":"additional","affiliation":[{"name":"National Institute for Clinical Excellence; Appraisals Team; 11 Strand London UK WC1N 5HR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Judd","sequence":"additional","affiliation":[{"name":"Canadian Health Services Research Foundation\/Fondation canadienne de la recherche sur les services de sant\u00e9; Research Use\/Agente principale de programme, Utilisation de la Recherche; 1565 avenue Carling Avenue Suite\/pi\u00e8ce 700 Ottawa ON Canada K1Z 8R1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[{"name":"University of Ottawa; Department of Epidemiology and Community Medicine; 501 Smyth Road Ottawa ON Canada K1H 8L6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanveer","family":"Towheed","sequence":"additional","affiliation":[{"name":"Queen's University; Department of Medicine and of Community Health and Epidemiology; Etherington Hall-Room 2066 Kingston ON Canada K7L 3N6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa; Department of Medicine; Ottawa ON Canada K1H 8M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"University of Ottawa; Department of Epidemiology and Community Medicine; 501 Smyth Road Ottawa ON Canada K1H 8L6"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"issue":"9196","key":"10.1002\/14651858.CD003831.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","article-title":"Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison","volume":"354","author":"Emery","year":"1999","journal-title":"Lancet"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003831.pub2-BIB2|cit2","first-page":"Abstract 1699","article-title":"Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis [abstract]","volume":"41","author":"Geis","year":"1998","journal-title":"Arthritis & Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD003831.pub2-BIB3|cit3","first-page":"2606-abstract 1","article-title":"Serial endoscopies confirm lower incidence of gastroduodenal ulceration with celecoxib as compared to naproxen [abstract]","volume":"94","author":"Burr","year":"1999","journal-title":"American journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003831.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1572-0241.2001.03740.x","article-title":"Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase -2 inhibitor, compared to naproxen in patients with arthritis","volume":"96","author":"Goldstein","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003831.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1365-2036.2004.01956.x","article-title":"Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis","volume":"19","author":"A. J.","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1002\/14651858.CD003831.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00044011-200424020-00004","article-title":"Satety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis","volume":"24","author":"Wen","year":"2004","journal-title":"Clin Drug Invest"},{"key":"10.1002\/14651858.CD003831.pub2-BIB7|cit7","unstructured":"CLASS Advisory Committee Briefing document CLASS Advisory Committee. Briefing documment. www.fda.gov\/OHRMS\/dockets\/AC\/01\/briefing\/367761_01_searle.pdf 2001. 2860748"},{"issue":"10","key":"10.1002\/14651858.CD003831.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD003831.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","article-title":"Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects","volume":"41","author":"Simon","year":"1998","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003831.pub2-BIB10|cit10","first-page":"Abstract 1990","article-title":"Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis [abstract]","volume":"41","author":"Geis","year":"1998","journal-title":"Arthritis & Rheumatism"},{"issue":"20","key":"10.1002\/14651858.CD003831.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","article-title":"Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial [see comments]","volume":"282","author":"Simon","year":"1999","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD003831.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/1529-0131(200004)13:2<112::AID-ANR5>3.0.CO;2-L","article-title":"Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib","volume":"13","author":"Zhao","year":"2000","journal-title":"Arthritis Care & Research"},{"issue":"26","key":"10.1002\/14651858.CD003831.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa021907","article-title":"Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis","volume":"347","author":"Francis K.L.","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"suppl 9","key":"10.1002\/14651858.CD003831.pub2-BIB14|cit14","first-page":"Abstract 373","article-title":"A pilot endoscopic study of the gastroduodenal effects of SC-58635, a COX-2 selective inhibitor. [abstract]","volume":"40","author":"Lanza","year":"1997","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD003831.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/00912700022008766","article-title":"Effects of celecoxib, a novel cyclooxygenase-2 inhibitor on platelet function in healthy adults: a randomized, controlled trial","volume":"40","author":"Leese","year":"2000","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD003831.pub2-BIB16|cit16","first-page":"9","article-title":"Outcome of specific COX-2 inhibition in rheumatoid arthritis","volume":"24 Suppl 49","author":"Lipsky PE","year":"1997","journal-title":"J-Rheumatol"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003831.pub2-BIB17|cit17","first-page":"Abstract 1352","article-title":"Early experience with selective COX-2 inhibitors; safety profile in over 340,000 patient years of use [abstract]","volume":"42","author":"Singh","year":"1999","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD003831.pub2-BIB18|cit18","unstructured":"Rosenberger   L Revised integrated clinical and statistical report for a pilot dose-ranging study to evaluate the safety and efficacy of SC-58635 40mg, 100mg nad 200mg bid versus placebo in treating the signs and symptoms of osteoarthritis. [Searle Study 13 - unpublished] 2860768"},{"key":"10.1002\/14651858.CD003831.pub2-BIB19|cit19","volume-title":"British National Formulary","author":"BNF","year":"2002"},{"key":"10.1002\/14651858.CD003831.pub2-BIB20|cit20","article-title":"Advisory Commitee Briefing Document: Review of Celecoxib Long-Term Arthritis Safety Study (CLASS)","author":"FDA Briefing","journal-title":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b1.htm"},{"key":"10.1002\/14651858.CD003831.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1002\/14651858.CD003831.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1002\/14651858.CD003831.pub2-BIB23|cit23","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012095.pub2","article-title":"Celecoxib for rheumatoid arthritis","author":"Fidahic","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003831.pub2-BIB24|cit24","article-title":"Rofecoxib in the treatment of rheumatoid arthritis","author":"Garner","year":"2002","journal-title":"The Cochrane Library"},{"key":"10.1002\/14651858.CD003831.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised controlled trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD003831.pub2-BIB26|cit26","unstructured":"Hong Laura   Lu Statistical reviewer briefing document for the Arthritis Advisory Committee http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b1_04_stats.doc 2000"},{"key":"10.1002\/14651858.CD003831.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3111\/199902045055","article-title":"Cost of NSAID adverse events in the UK NHS","volume":"2","author":"Moore","year":"1999","journal-title":"Journal of Medical Economics"},{"key":"10.1002\/14651858.CD003831.pub2-BIB28|cit28","unstructured":"OMERACT Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials 1993 526 91"},{"issue":"8","key":"10.1002\/14651858.CD003831.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/1529-0131(199908)42:8<1572::AID-ANR2>3.0.CO;2-G","article-title":"ACR20: clinical or statistical significance?","volume":"42","author":"Pincus","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1002\/14651858.CD003831.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003831.pub2-BIB31|cit31","first-page":"811","article-title":"Epidemiology and rheumatic diseases","volume-title":"Oxford Textbook of Rheumatology","author":"Silman","year":"1998"},{"issue":"47","key":"10.1002\/14651858.CD003831.pub2-BIB32|cit32","first-page":"3","article-title":"Low dose etodolac in rheumatoid arthritis: a review of early studies","volume":"Supplement","author":"Spencer-Green","year":"1997","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003831.pub2-BIB33|cit33","article-title":"Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip.","author":"Towheed","year":"2000","journal-title":"Cochrane Library"},{"key":"10.1002\/14651858.CD003831.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annual Review of Pharmacology & Toxicology"},{"issue":"2","key":"10.1002\/14651858.CD003831.pub2-BIB35|cit35","article-title":"Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee","author":"Watson","year":"2000","journal-title":"Cochrane Library"},{"issue":"24","key":"10.1002\/14651858.CD003831.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Medical progress: gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"NEJM"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003831.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:33:16Z","timestamp":1701131596000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003831.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003831.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,9]]}}}